Selection of blockbuster announcements

1. Nuohui Health Yingxi: total revenue in 2022 is expected to be 7.51-783 million yuan, an increase of 252.7% to 267.7% over the same period last year.

$NH HEALTH-B (06606.HK)$According to the announcement, total revenue in 2022 is expected to be 7.51-783 million yuan, an increase of 252.7 percent to 267.7 percent over the same period last year. In the same period, gross profit is expected to be 639-656 million yuan, an increase of 313.2% to 324.5% over the same period last year. Mainly due to the increase in product revenue, gross profit margin in 2022 is expected to rise 81.6% year-on-year to 87.4%.

2. China CITIC Bank Corporation: the net profit in 2022 was 62.1 billion yuan, an increase of 12% over the same period last year.

$CITIC BANK (00998.HK)$KuaiBao posted an operating income of 211.382 billion yuan in 2022, an increase of 3.34 percent over the previous year, while the net profit belonging to the bank's shareholders was 62.103 billion yuan, an increase of 11.61 percent over the previous year. By the end of 2022, the bank's non-performing loan ratio was 1.27%, down 0.12 percentage points from the end of last year, and the provision coverage ratio was 201.33%, an increase of 21.26 percentage points over the end of last year.

3. CITIC: net profit in 2022 was 21.1 billion yuan, down 8.6% from the same period last year.

$CITIC (06030.HK)$KuaiBao released results, achieving operating income of 65.533 billion yuan in 2022, down 14.36 percent from the same period last year; realizing net profit of 21.121 billion yuan belonging to shareholders of the parent company, down 8.57 percent from the same period last year; and net profit of 20.706 billion yuan after deducting non-recurring profits and losses belonging to shareholders of the parent company, down 11.19 percent from the same period last year; basic earnings per share 1.41 yuan.

4. China Resources cement Holdings: the annual profit is expected to decrease by about 74% and 78% compared with the same period last year.

$CHINARES CEMENT (01313.HK)$A profit warning was issued on the Hong Kong stock exchange, and according to a preliminary assessment of the group's unaudited consolidated management accounts, profits attributable to company owners are expected to fall by about 74 per cent to 78 per cent year-on-year in 2022. The main reasons are: (1) the increase in the unit cost of sales of group cement products; (2) the decline in the sales volume of group products; and (3) the decrease in the average sales price of cement and clinker in the business operation area of the group.

5、China Communications Construction: no more than 300 million preferred shares will be issued, with a total of no more than 30 billion yuan

$CHINA COMM CONS (01800.HK)$To disclose the pre-plan for the non-public offering of preferred shares in 2023, the number of preferred shares issued shall not exceed 300 million shares, and the total amount of funds raised shall not exceed 30 billion yuan. The preferred shares will be issued in a non-public manner to no more than 200 qualified investors who comply with the pilot measures for the Administration of preferred shares and other laws and regulations. The par value of each preferred share is RMB 100, which is issued at par value, and all issuers are subscribed in cash. All the net funds raised after deducting the issuance expenses will be used to replenish the working capital.

6. Heplatinum Pharmaceutical-B:HBM1020 clinical trial was approved by the US Food and Drug Administration for new drug research.

$HBM HOLDINGS-B (02142.HK)$It was announced that the company has obtained the New Drug Research license (IND) of the US Food and Drug Administration (FDA) to launch a clinical trial of monoclonal antibody HBM1020 (also the world's first similar product targeting B7H7) in the United States. This trial is a phase I, open-label, multicenter study to evaluate the safety, tolerance, pharmacokinetics and antitumor activity of HBM1020 in patients with advanced solid tumors. HBM1020 is also the world's first monoclonal antibody targeting B7H7 approved by regulators to conduct clinical trials.

Listing of new shares

Wang Dust Technology Holdings (02458) Hong Kong offering shares are slightly oversubscribed and the offer price is set at HK $6.50 per share

Beautiful Garden Medical and Health (02373) Hong Kong offering shares are oversubscribed at HK $19.32 per share.

The Hong Kong offering shares of Baiguo Garden Group (02411) were substantially oversubscribed and the price was set at HK $5.60 per share.

Financial performance

Nuohui Health (06606) Yingxi: expected annual gross profit increased by 313.2% to 324.5%

China Resources cement Holdings (01313) announced earnings warning: annual profit is expected to decrease by about 74% and 78% compared with the same period last year.

CITIC (06030) net profit of 21.121 billion yuan in 2022 decreased 8.57% compared with the same period last year.

China CITIC Bank Corporation (00998) performance KuaiBao: net profit of 62.1 billion yuan in 2022, an increase of 11.61% over the same period last year

Fast Retailing (06288) Total Consolidated income in the first quarter increased by 14.2% to 716.3 billion yen. Chinese mainland business profit dropped sharply.

Revenue of Dechang Motor Holdings (00179) reached US $2.521 billion in the first three quarters of the year. Revenue in the automotive product group increased by 11% compared with the same period last year.

Operation data

The People's Insurance (01339): the original premium income of 619.158 billion yuan in 2022 increased by 6.56% over the same period last year.

PICC Property and Casualty's original premium income totaled 485.434 billion yuan in 02328, an increase of 8.3% over the same period last year.

Zhongjun Group Holdings (01966): cumulative contract sales of 59.023 billion yuan in 2022

China Resources Land (01109) the total contract sales in December 2022 is about 49.59 billion yuan, an annual increase of 9.8%.

Liufu Group (00590) has a net increase of 106 stores in the mainland in the third quarter, of which 82 are "Liufu" stores.

China Longyuan Power Group Corporation (00916): a total of 70.633 million megawatts of electricity generated in 2022 increased by 11.61% over the same period last year.

BOC Aviation Leasing (02588): receiving 34 new aircraft in 2022 and handing over 21 second-hand aircraft to airline customers

Yuexiu Transportation Infrastructure (01052): the toll income of Humen Bridge in November was 53.304 million yuan lower than the same period last year.

Investment and operation

And Platinum Pharmaceuticals-B (02142): HBM1020 Clinical trial launched with New Drug Research license from the US Food and Drug Administration

Hongqiao Group (08137) received about 77.5% discount from Geely Group to make a takeover offer.

China Communications Construction (01800) plans to issue no more than 300 million preferred shares with a total of no more than 30 billion yuan

Hainer Star Technology (08297) plans to join hands with Zhongtianpingkang to develop "Great Health" e-commerce online platform and "Great Health" related products.

Shandong Gold Mining (01787) plans to jointly invest with Gansu Capital Management to establish Gansu Jinqiao Mining Industry.

Shandong Xinhua Pharmaceutical Co., Ltd. (00719): notice of approval of drug clinical trial of OAB-14 dry suspension declared by the company

Cofco Packaging (00906): a second joint venture plant of aluminum two-piece cans to be opened in Central and Eastern Europe

Dream World (01119): the new game "Beware of Fire" was officially launched in Chinese mainland on January 11th.

Repurchase cancellation

Tencent (00700) spent HK $352 million to buy back 960000 shares on January 12.

AIA Group Limited (01299) spent HK $225 million to buy back 2.5798 million shares on January 12.

ESR Cayman Limited (01821) spent HK $7.443 million to buy back 450000 shares on January 12.

Sinotrans (00598) spent HK $2.3752 million to buy back 909000 shares on January 12.

Equity incentive

Xinyi.com Group (01686) granted 10.4 million share options

Edit / somer